AbCellera (ABCL) Q2 2026 Earnings Call Transcript

AbCellera reported Q2 2026 revenue of ~$4.1M, down from ~$17.1M in Q2 2025, with a net loss of ~$55.4M (loss of $0.18/share) versus ~$34.7M a year earlier. Liquidity remains supportive, with total cash and marketable securities at ~$567M and available liquidity of $675M (including ~$110M committed government funding), and it expects existing liquidity to fund pipeline investments for at least three years. Near-term catalysts include completion of Phase 2 enrollment for ABCL635 with top-line data expected in August 2026, alongside $56M upfront received from Jazz Pharmaceuticals (and potential additional $28M) and $28M upfront from Vertex, with total potential Jazz deal value over $4B.

Analysis

ABCL is no longer a simple platform story; it is now a two-legged equity: near-term binary on ABCL635 and longer-dated optionality from partner validation. The Jazz and Vertex deals reduce the probability of a financing overhang, so the stock should not trade like a distressed preclinical biotech unless the readout fails. That said, most of the headline partnership value is contingent and delayed, so near-term multiple expansion still depends on clinical evidence rather than deal rhetoric.

The cleanest winners are JAZZ and VRTX, because they are buying asymmetric discovery access without taking balance-sheet or execution risk at the same magnitude as ABCL. For JAZZ, the upside is not the upfront cash-outlay itself but the possibility of a productive TCE engine that can refresh a maturing pipeline; for VRTX, this is a cheap option on a new modality adjacent to its immunology franchise. On the loser side, any credible non-hormonal hot-flash incumbent and the broader NK3R class face a convenience/safety challenge if ABCL635 shows comparable efficacy with no liver or somnolence baggage.

The key risk is not liquidity; it is whether the biology translates at the exact efficacy bar investors care about after a placebo-heavy study design. A miss would likely compress the multiple quickly because the market has little patience for "platform validation" when the lead internal asset fails. The contrarian view is that consensus may be underpricing the cash runway and partner traction, but overpricing the monetization of those $4B headline numbers: most of that value sits several clinical gates away, so the stock should still be treated as an event-driven name, not a de-risked compounder.

Key Decisions for Investors

• Buy a small tactical ABCL call spread into the August top-line readout only if implied move is below the historical event risk; target a 2-3x payout on a clean efficacy/safety beat, and cut immediately if placebo-adjusted frequency benefit or liver enzymes disappoint.
• Prefer JAZZ over ABCL for investors wanting exposure to the TCE thesis without a binary clinical event; the partnership adds low-capex pipeline optionality over 6-18 months with less downside from one trial.
• Use VRTX as the higher-quality way to express optimism on multispecific TCEs in autoimmunity; the read-through is strategic, not immediate, but downside is limited versus owning ABCL into a catalyst.
• If ABCL635 data are merely "good" rather than clearly differentiated, fade the initial spike in ABCL and rotate into BAYRY weakness as a proxy short for the NK3R/non-hormonal VMS incumbents losing share narrative.
• No pre-readout outright short in ABCL unless the stock re-rates far ahead of data; the balance sheet and partnership backstop make the downside asymmetric only if the clinical thesis breaks.